GlaxoSmithKline beats profit forecasts despite Advair hit, lower margins
A further slide in sales of lung drug Advair and lower profit margins following a business overhaul hit GlaxoSmithKline in the second quarter, although core earnings per share fell by a less than expected 9 percent.
Jul 29, 2015, 18:03 PM IST